Researchers at Dana-Farber Cancer Institute, in collaboration with colleagues from Memorial Sloan Kettering Cancer Center in New York (Dr. Kai Rejeski) and the LMU Hospital in Munich, Germany (Dr. Tobias Tix), have found that infections were the main driver of non-relapse mortality in patients receiving chimeric antigen receptor (CAR) T-cell therapy.
Medical Xpress – latest medical and health news stories
Discover more from Nurse Unity Chats
Subscribe to get the latest posts sent to your email.
